PA1-914

antibody from Invitrogen Antibodies

Targeting: ATP2B1 PMCA1

Western blot

ELISA

Immunohistochemistry

Antibody data

Submit

Validation data

Product number: PA1-914 - Provider product page
Provider: Invitrogen Antibodies
Product name: PMCA1 ATPase Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Synthetic peptide
Description: PA1-914 detects calcium pump of the plasma membrane 1a (PMCA1a ATPase) and 1b from rat, human and porcine tissues. PA1-914 has been successfully used in Western blot, immunohistochemistry (paraffin and frozen), and ELISA procedures. By Western blot, this antibody detects ~134 kDa and ~130 kDa proteins representing PMCA1a and 1b ATPase from rat, human and porcine samples. The PA1-914 immunogen is a synthetic peptide corresponding to the residues A(5) N N S V A Y S G V K N S I K E A N(22) of rat PMCA1 ATPase.
Reactivity: Human, Rat, Porcine
Host: Rabbit
Isotype: IgG
Vial size: 100 µg
Concentration: 1 mg/mL
Storage: -20° C, Avoid Freeze/Thaw Cycles

ATP2B1 protein structure - PA1-914 shown in red.

Supportive validation

Supportive validation

Supportive validation

Supportive validation

Supportive validation

Supportive validation

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Combination treatment with the mutant BRAF inhibitor vemurafenib and histone deacetylase inhibitors (HDACi) . BRAF wild-type MEWO and BRAF-mutant A375 and A2058 cells were treated with the mutant BRAF inhibitor vemurafenib (0.5 uM), HDACi SAHA (1 uM), and valproate (2 mM) alone or in combination for 48 h. After Western blotting expression of PMCA4b, PMCA1, SERCA2, SERCA3, pERK, and ERK proteins were analyzed. As a positive control of PMCA1 and PMCA4b, total cell lysate of COS-7 cells was used, which endogenously express both proteins ( 9 ). (A) The expression of PMCA proteins was detected with isoform-specific and pan-PMCA antibodies. (B) After densitometric analysis, changes in PMCA4b (B) , ERK (C) and SERCA2 (D) protein levels were normalized to the expression levels of beta-tubulin and expressed as fold increase over the untreated controls. Bars represent mean +- SE from three independent experiments. Significance compared to control is denoted by asterisks (* p < 0.05), using two-tailed paired t -test.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: 3 Effect of silencing VDR gene expression on Ca 2+ -transport proteins expression levels in NRK cells. Western blot for VDR, TRPV5, TRPV6, calbindin-D 28K , PMCA1b, and NCX1 from AdmiVDR- and Negative-vector infected NRK cells at different time points.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Expression of PMCA isoforms in multiple pancreatic cell lines. ( A ) Representative Western immunoblot showing the relative protein expression of total/pan-PMCA and PMCA isoform 1-4 in pancreatic cancer (MIA PaCa-2 and PANC-1) and non-malignant pancreatic cells (human pancreatic ductal epithelial (HPDE) and human pancreatic stellate cells (hPSC)). Mouse brain lysate was used as a positive control for PMCA expressions and beta-Actin was used as a protein loading control. ( B ) PMCA4 protein expression in each cell line was quantified from Western blot bands and normalized to beta-Actin housekeeping protein. ( C ) The relative expressions of ATP2B1-4 (PMCA1-4 mRNA) in each cell line were quantified by RT-qPCR. Data are expressed as relative mRNA expression normalized to corresponding S18 rRNA controls (2 -DeltaCtau ). Statistical comparisons were made using the Kruskal-Wallis test with Dunn's multiple comparison test and two-way analysis of variance (ANOVA) with Dunnett's multiple comparison test. Data are expressed as mean +- SEM. (n = 4-5, 4 replicates per treatment condition). * represents statistical significance where p < 0.05.